1. Academic Validation
  2. Gomisin J Inhibits Oleic Acid-Induced Hepatic Lipogenesis by Activation of the AMPK-Dependent Pathway and Inhibition of the Hepatokine Fetuin-A in HepG2 Cells

Gomisin J Inhibits Oleic Acid-Induced Hepatic Lipogenesis by Activation of the AMPK-Dependent Pathway and Inhibition of the Hepatokine Fetuin-A in HepG2 Cells

  • J Agric Food Chem. 2015 Nov 11;63(44):9729-39. doi: 10.1021/acs.jafc.5b04089.
Myungsuk Kim 1 Sue Ji Lim 1 2 Hee-Ju Lee 1 Sun Young Kim 1 Chu Won Nho 1
Affiliations

Affiliations

  • 1 Natural Products Research Center, Korea Institute of Science and Technology (KIST) Gangneung Institute , Gangwon 210-340, Korea.
  • 2 Department of Chemistry, Gangneung-Wonju National University , Gangneung, Gangwon-do 210-702, Korea.
Abstract

The aim of our study is to investigate the molecular mechanism of gomisin J from Schisandra chinensis on the oleic acid (OA)-induced lipid accumulation in HepG2 cells. Gomisin J attenuated lipid accumulation in OA-induced HepG2 cells. It also suppressed the expression of lipogenic enzymes and inflammatory mediators and increased the expression of lipolytic enzymes in OA-induced HepG2 cells. Furthermore, the use of specific inhibitors and fetuin-A siRNA and liver kinase B1 (LKB1) siRNA transfected cells demonstrated that gomisin J regulated lipogenesis and lipolysis via inhibition of fetuin-A and activation of an AMP-activated protein kinase (AMPK)-dependent pathway in HepG2 cells. Our results showed that gomisin J suppressed lipid accumulation by regulating the expression of lipogenic and lipolytic enzymes and inflammatory molecules through activation of AMPK, LKB1, and Ca(2+)/calmodulin-dependent protein kinase II and inhibition of fetuin-A in HepG2 cells. This suggested that gomisin J has potential benefits in treating nonalcoholic fatty liver disease.

Keywords

AMPK; CaMKII; LKB1; fetuin-A; gomisin J.

Figures
Products